In-vivo measurement of activated microglia in dementia

Lancet

Volumn 358, Issue 9280, 2001, Pages 461-467

  Cagnin, Annachiara ^a   Brooks, David J ^a,b   Kennedy, Angus M ^a   Gunn, Roger N ^a   Myers, R ^a   Turkheimer, Federico E ^a   Jones, Terry ^a   Banati, Richard B ^a,c,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; LIGAND; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CELL ACTIVATION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HUMAN; IN VIVO STUDY; MALE; MICROGLIA; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL CORTEX; THALAMUS;

EID: 0035845283     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05625-2     Document Type: Article

References (30)

1. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
2. Microglia: A sensor for pathological events in the CNS
3. Über eigenartige krankheitsfälle des späteren alters
4. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.
5. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid
6. NSAIDs and incident Alzheimer's disease: The Rotterdam Study
7. PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: Microautoradiographic detection of [3H]PK11195 binding to activated microglia
8. Temporal changes in glial fibrillary acidic protein messenger RNA and [3H]PK11195 binding in relation to imidazoline-I2-receptor and alpha 2-adrenoreceptor binding in the hippocampus following transient global forebrain ischaemia in the rat
9. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anaesthetised baboon
10. The peripheral benzodiazepine binding sites in the brain in multiple sclerosis: Quantitative in vivo-imaging of microglia as a measure of disease activity
11. Binding characteristics of the receptor and coupling to transport proteins
12. Mild cognitive impairment: Clinical characterisation and outcome
13. Simplified reference tissue model for PET receptor studies
14. Parametric imaging of ligand-receptor interactions using a reference tissue model and cluster analysis
15. Evidence of a smaller left hippocampus and left temporal horn in both patients with first episode schizophrenia and normal control subjects
16. 18FDG-PET study
17. Spectral analysis of dynamic PET studies
18. Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images
19. In vivo evaluation in mice and metabolism in blood of human volunteers of [123I]iodo-PK11195: A possible single-photon emission tomography tracer for visualization of inflammation
20. Ageing and dementia
21. (3H) PK 11195 and the localisation of secondary thalamic lesions following focal ischemia in rat motor cortex
22. Displacement of synaptic terminals from regenerating motoneurons by microglial cells
23. The processing-speed theory of adult age differences in cognition
24. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease
25. Synthesis of the enantiomer of [N-methyl-11C]PK11195 and comparison of their behaviours as PK (peripheral benzodiazepine) binding site radioligands in rats
26. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
27. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
28. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and cortices in the non-human primate as shown by PET: Implications for Alzheimer's disease
29. Tangles and plaques in nondementedaging and "preclinical" Alzheimer's disease
30. Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals